Key clinical point: Patients who develop RCC before age 47 typically have comorbidities that place them at an increased risk for chronic kidney disease and end-stage renal disease. Partial nephrectomy is even more critical to pursue if deemed feasible in this at-risk population. Only 2/96 (2.1%) patients in the early onset RCC group had disease recurrence.
Major finding: Compared to the control group, early onset RCC patients were more likely to undergo a partial nephrectomy (P = .002) and 78% of patients presented with stage 1a (52/91) or 1b (19/91) disease. In the control group, 67% of patients presented with stage 1a (234/500) or 1b (101/500) disease. In the early onset RCC group, 9/91 (9.9%) patients presented with stage 3 disease, compared to 120/500 (24%) patients in the control group.
Study details: A retrospective search of a surgical pathology database performed from 2011 to 2016 identified 598 RCCs in 576 patients. In the early onset RCC group, 98 (16.4%) RCCs occurred in 96 patients. The remaining 500 (83.6%) RCCs occurred in 480 patients older than 46 years, which comprised the control group.
Disclosures: The researchers had no relevant financial disclosures.
Source: Clemmensen T et al. Human Pathology April 2018 25-31. https://doi.org/10.1016/j.humpath.2017.11.005
Clemmensen T et al. Human Pathology April 2018 25-31. https://doi.org/10.1016/j.humpath.2017.11.005
This Week's Must Reads
Federal guidelines clearinghouse to shutdown July 16, 2018, www.guidelines.gov
CMS freezing of risk adjustment payments predicted to drive up insurance premiums, United States District Court Ruling Puts Risk Adjustment On Hold
If confirmed as Supreme Court justice, Kavanaugh could upend ACA, Case references, including Seven-Sky v. Holder
Software boosts accuracy of colonoscopies, Tripathi PV et al. DDW 2018 (Digestive Disease Week, 2018). Presentation 133.
Proposed fee schedule for 2019 could cut EHR hours, https://s3.amazonaws.com/public-inspection.federalregister.gov/2018-14985.pdf
Must Reads in Renal Cell Carcinoma
EBUS-TBNA guides need for further treatment in RCC, Val-Bernal J et al. Pathology Research and Practice 2018; 214 (7), 949-56.
Clear cell papillary RCC distinguished by unique staining pattern, Wang Y et al. Annals of Diagnostic Pathology 36: 2018; 1-4. https://doi.org/10.1016/j.anndiagpath.2018.06.007
Myelodysplasia risk high in RCC patients, Shenoy N et al. Clinical Genitourinary Cancer, Published online June 28, 2018. https://doi.org/10.1016/j.clgc.2018.06.008
Pembrolizumab in advanced clear cell RCC, McDermott DF et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 4500.
Do docetaxel nanoparticles boost response in mCRPC?, Autio KA et al. JAMA Oncol. 2018 July 5. doi: 10.1001/jamaoncol.2018.2168.